Rituximab (R) maintenance has shown clinical benefit for patients with follicular lymphoma (FL)



Yüklə 404 Kb.
tarix01.07.2018
ölçüsü404 Kb.
#52474



Rituximab (R) maintenance has shown clinical benefit for patients with follicular lymphoma (FL):

  • Rituximab (R) maintenance has shown clinical benefit for patients with follicular lymphoma (FL):

    • In the relapsed setting after induction with chemotherapy alone or chemotherapy plus R (J Clin Oncol 2010;28:2853).
    • In the first-line setting after induction chemotherapy alone1 or R alone2 (1 J Clin Oncol 2009;27:1607, 2 Blood 2004;103:4416).
  • The role of R maintenance in FL after first-line R-chemotherapy induction remains unknown.

  • Current study objective:

    • Assess the benefit of R maintenance over the course of two years for patients with FL responding to first-line R-chemotherapy induction.












R maintenance for two years significantly improved PFS for patients with previously untreated FL who responded to induction with chemotherapy plus R.

  • R maintenance for two years significantly improved PFS for patients with previously untreated FL who responded to induction with chemotherapy plus R.

  • Benefits of R maintenance were seen in all major sub-groups.

  • Consistent improvements were observed in secondary endpoints including CR, OR and time to next treatment (data not shown).

  • The results of the PRIMA study provide evidence for a new standard of care for patients with FL who are in need of initial treatment.

  • Data from the ongoing ECOG-E4402 (RESORT) trial will address how maintenance R compares to re-treatment with R at disease progression.










Yüklə 404 Kb.

Dostları ilə paylaş:




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2022
rəhbərliyinə müraciət

    Ana səhifə